Opportunity for Improved Menopausal Hormone Therapy Prescribing
Authors:
Top Cited Papers
- 21 April 2026
- journal article
- perspective
- Published by American Medical Association (AMA) in JAMA
- Vol. 335 (15) , 1297
Abstract
This Perspective discusses the implications of the recent US Food and Drug Administration (FDA) label change on menopausal hormone therapy for clinicians to better integrate hormone therapy options and personalized, shared decision-making to improve care for midlife women.Keywords
This publication has 18 references indexed in Scilit:
- Updated Labeling for Menopausal Hormone TherapyJAMA, 2026
- The Women’s Health Initiative Randomized Trials and Clinical PracticeJAMA, 2024
- Impact of Menopause Symptoms on Women in the WorkplaceMayo Clinic Proceedings, 2023
- Management of Menopausal SymptomsJAMA, 2023
- Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal PersonsJAMA, 2022
- Menopause and healthcare professional education: A scoping reviewMaturitas, 2022
- Assessment of the climacteric syndrome: a narrative reviewArchives of Gynecology and Obstetrics, 2021
- Global Consensus Position Statement on the Use of Testosterone Therapy for WomenThe Journal of Sexual Medicine, 2019
- Impact of estrogen type on cardiovascular safety of combined oral contraceptivesContraception, 2016
- Duration of Menopausal Vasomotor Symptoms Over the Menopause TransitionJAMA Internal Medicine, 2015